www.wjpps.com Vol 9, Issue 6, 2020.
673
Suresh et al. World Journal of Pharmacy and Pharmaceutical Sciences
EPIDEMIC 2019-20 - COVID-19 CURRENT SCENARIO
Rajni Sawanny1, Deepa Bajetha
1, Vikas Sharma
1 and Suresh Kumar Joshi
2*
1Noida Institute of Engineering and Technology (Pharmacy Institute), Plot
No. 19,
Knowledge Park-II Institutional area Greater Noida, Uttarpradesh- 201306 India.
2Amerise Pharmaceuticals Pvt. Ltd, Ahmedabad, Gujarat, Pin-380060, India.
ABSTRACT
As per World Health Organization (WHO) viral ailments continued to
develop and affect a serious issue on the populace. most recent twenty
year’s numerous viral plagues like respiratory disorder coronavirus
(SARS-COV) in 2002 – 2003, H1N1 flu in 2009 have been archived,
as of late Middle East respiratory disorder coronavirus (MERS-COV)
was first seen in Saudi Arabia in 2012. At present bottomless
unexplored low respiratory diseases cases recognized in Wuhan, the
broad metropolitan territory in China's Hubei region, was first
answered to the WHO Country Office in China, on December 31,
2019. The causative specialist isn't distinguished at this point, first case is "pneumonia of
obscure etiology." The Chinese Center for Disease Control and Prevention (CDC) and
neighborhood CDCs requested an extreme episode examin On Feb 11, 2020 the WHO
Director-General, Dr. Tedros Adhanom Ghebreyesus pronounce that the infection brought
about by this new CoV was a "COVID-19,". By SARS-CoV broad scourge starting in China
and influence two dozen countriesaround 8000 cases and 800 passings, and the MERS-CoV
that started in Saudi Arabia and has around 2,500 cases and 800 passings and still causes rare
cases.
KEYWORDS: SARS-CoV, Pandemic, GDP, CDC etc.
INTRODUCTION
In current scenario COVID-19 arises as a headache in entire world, which is an infectious
disease caused by a newly discovered coronavirus. The spotting and spreading of respiratory
pathogen and its power and potential to outspread in human population acrimony (severity
WORLD JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES
SJIF Impact Factor 7.632
Volume 9, Issue 6, 673-697 Review Article ISSN 2278 – 4357
WORLD JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES
SJIF Impact Factor 7.632
Volume 9, Issue 6, XXX-XXX Review Article ISSN 2278 – 4357
Article Received on
15 April 2020,
Revised on 05 May 2020,
Accepted on 25 May 2020
DOI: 10.20959/wjpps20206-16332
*Corresponding Author
Suresh Kumar Joshi
Amerise Pharmaceuticals
Pvt. Ltd, Ahmedabad,
Gujarat, Pin-380060, India.
www.wjpps.com Vol 9, Issue 6, 2020.
674
Suresh et al. World Journal of Pharmacy and Pharmaceutical Sciences
and harmfulness of a disease). It is spotted in 2019(COVID-19) coronavirus disease 2019,1st
detected in Wuhan City, in China December 2019.[1]
This new infection is transmittable and spread out quickly all over , this flare-up was reported
by the WHO a Public Health Emergency of International Concern (PHEIC) in light of the
fact that it spread to 18 nations with 4 nations recorded human to human transmission. It has
know become a main pathogen of respiratory ailment episode, International Committee on
Taxonomy of Viruses (ICTV) titled it the SARS-CoV-2 infection as it is identified with the
one that caused the SARS flare-up (SARS-CoVs).
They are an enormous group of single-stranded RNA infections (+ssRNA) disconnected from
unmistakable creature species. They can likewise disregard species obstructions and prompt
ailment from normal virus to progressively genuine respiratory issue and malady MERS and
SARS. Later these infection are no doubt started in bates and afterward move to different
warm blooded creatures or host - the Himalayan palm civet for SARS-CoV, and the
dromedary camel for MERS-CoV — before move to people or host. This virus is capable to
grow and become epidemic a severe public health risk issue. World government are work to
establish antidotes for this decimate effects of virus, health organizations provide guidance,
instruction’s, flow chat, posters to relieve or alleviate the effects and impression of this risk.
The virus came in contact with the host and the host connect with the surrounding and effect
all others by shaking hands, hug, sneeze, touching utensils etc. To avoid spreading this
infected host must avoid crowded areas such as, meetings, malls, office, schools, markets etc.
and quarantine himself.[2]
Etiology
The viral genome investigation starting report recognize that infection shares 88%
arrangement like two terrible inferred extreme intense respiratory disorder (SARS) like
coronavirus yet altogether different from serious intense respiratory disorder coronavirus
(SARS-CoV). Extraordinarily; homology demonstrating disclose that 2019-nCoV had the
same receptor-restricting area structure to that of SARS-CoV, in spite of amino corrosive
variety at some key deposits.[3]
So for the time being it’s called extreme intense respiratory disorder coronavirus (Harsco).
crown infection is bounded(enveloped) and single standard ribonucleic corrosive named for
its sun oriented crown like similarity by reason of 9-12 nm-long surface spikes. The
www.wjpps.com Vol 9, Issue 6, 2020.
675
Suresh et al. World Journal of Pharmacy and Pharmaceutical Sciences
measurement of infection partials is lie within the range between 60–140 nm and show
circular shape with surprising or some pleomorphic.[4]
Table 1: First strain of COVID-19 - Basic information[4]
Descriptors Description
Name C-Tan-nCoV Wuhan Strain
Scientific classification Novel β genus coronavirus
Wellspring of the Specimen Clinical Patients
Wellspring of Collection Wuhan, Hubei Province, China
Confinement Date Jan 6, 2020
Hazard Level BSL-3
Beta coronavirus S proteins are prepared into S1 and S2 subunits by have proteases.[5]
Among 4 significant basic proteins encoded by corona viral genome on the envelope, in
which on is spike (S) protein partner with the cell receptors (angiotensin-changing over
catalyst 2 (ACE2)) to impact target cells and disease happen by this combination among
envelope and host cell film and viral enter in have cell. Hostile to ACE2 yet not against
ACE1 counter acting agent blocked viral replication on Vero E6 cells, show that ACE2 is a
utilitarian receptor for SARS-CoV.[6,7,8]
On Febrary11, 2020, the Coronavirus Study Group (CSG) of the International Committee on
Taxonomy of Viruses, at long last reason that it is a genuine respiratory disorder coronavirus
2 (SARS-CoV-2) and characterize infection and taxa of ―Coronaviridae‖ family dependent on
phylogeny, scientific classification and set up training. The CGS relize that thios infection is
www.wjpps.com Vol 9, Issue 6, 2020.
676
Suresh et al. World Journal of Pharmacy and Pharmaceutical Sciences
like (SARS-CoVs) extreme intense respiratory disorder coronaviruses assigns it as serious
intense respiratory disorder coronavirus 2 (SARS-CoV-2). For additional comprehension of
host – infection communication explore are in procedure to improve readiness for future out
breaks.[9]
WHO named the illness instigate by this coronavirus as Coronavirus Disease 2019
(COVID-19).[10]
This flare-up is briefly connected with a fish advertise in Wuhan, China, where offer of wild
creatures may be source and root of zoonotic contamination. at present information it is see
that bat might be facilitated by COVID-19 may transmit to vertebrates by pangolin, it is
believing that pangolins are have for novel human infection ought to be disconnect from wet
markets to forestall zoonotic transmission. coronavirus similar to 2019-nCoV isolated from
a Rhinolophus affinis bat in Yunnan in 2013 has currently identified , closely related viruses
are not identified in other wildlife species.[11,12]
After investigate the virome design and
formation of pangolins (mammalian order Pholidota). They are increasingly influence and
now are in interest because they are illegally trafficked of any group of mammal: us e as food
source and traditional Chinese medicine. The novel pangolin coronavirus genomes have
around 85.5% to 92.4% similar to 2019-nCoV.[11]
To think about the developmental connection between SARS-CoV and its subordinates, 225
bats were gathered from Zhoushan city, Zhejiang territory, China, somewhere in the range of
2015 and 2017. PCR enhancement of the coronaviral protein RdRp distinguished
coronaviruses in 19.65% of bats of this district, and there tally was influenced via occasional
changes.by genomic investigations of the 2 new SL-CoVs (SARS-like coronaviruses)from
Zhoushan (ZXC21 and ZC45) uncover that their genomes were 29,732 nucleotides (nt) and
29,802 nt long, individually, with 13 open understanding edges (ORFs). this assessment
extend our keenness on the hereditary assorted variety of the SL-CoVs move by bats and give
a present perspective to examin the possibility of cross-species transmission of SL-CoVs
utilizing suckling rodents as a creature model. Flopped in confining the infection PCR-
positive examples in Vero E6 cells, they attempt to seclude infection from suckling rodents
by tainting them with tissue tests that were sure for the coronavirus. Following 14-15 days
obsessive investigations uncover that the incendiary response in the cerebrum tissues was
generally apparent and clear, the effect on the 10 suckling rodents are 4 show clinical side
effects, for example, sleepiness , moderate movement and mental wretchedness different
apoptotic neurons were found in the central regions of the mind tissue, and the chromatin in
www.wjpps.com Vol 9, Issue 6, 2020.
677
Suresh et al. World Journal of Pharmacy and Pharmaceutical Sciences
the cores was consolidated and hazy.[13]
different radiological assessments, for example,
slender cut chest CT assume a huge job in clashing and battling against irresistible disease.[14]
Likewise early stage lung disease analyze by Chest CT,[15]
conspicuous general wellbeing
observation and reaction frameworks.[16,17]
Table 2: Chest ct findings are disclosed of covid-19.[15,16,17]
CT findings Frequency (%)
Ground-glass haziness 86
Consolidation 28
Crazy-paving 19
Liner 14
Cavitation 0
Discrete nodules 0
Bilateral distribution 76
Peripheral distribution 33
Clinical Symptom’s, Characteristics of 2019 Novel Coronavirus Infection
Clinical symptoms intellect is very crucial, though they are recommended indefinite or non
specific. most common symptoms are fever, cough, myalgia or fatigue, tiredness, difficulty
in breathing ( in severe cases) those which have weak immune systems might suffer from
severe symptoms such as pneumonia or bronchitis, symptoms are might not identify after
being exposed to COVID-19. Many conform cases are observe in adults few in childrens,
there is no evince that children are in high risk for this virus. Other hand diarrhea have an
unusual data on, 1,099 patients with laboratory-confirmed 2019-nCoV ARD from 552
hospitals in 31 provinces/provincial municipalities through January 29th, 2020. The disease
intensity (addition to oxygen saturation, respiratory rate, chest X-ray/CT manifestations and
blood leukocyte/lymphocyte count) predict unsatisfactory clinical result. Laboratory findings,
signs and clinical symptoms extrat from electronic medical records. Radiologic estimates
chest X-ray or computed tomography. Laboratory calculations conclude the result of blood
chemistry, coagulation test, blood count, liver function, electrolytes, renal fuction, creatine
kinase, creatine kinase., creatine kinase, procalcitonin and lactate dehydrogenase.[18,19]
The clinical outcomes are the % of patients admit in the ICU necessitating ventilation and the
% of death are 5.00%, 2.18% and 1.36%, respectively,[19]
few patients suffer from headache
or hemoptysis[20]
and asymptomatic.[21]
older mans are more affected and have respiratory
failure as a result severe alveolar damage, even fatal respiratory diseases like acute
respiratory distress syndrome.. By imaging examination 70% patents show bilateral
www.wjpps.com Vol 9, Issue 6, 2020.
678
Suresh et al. World Journal of Pharmacy and Pharmaceutical Sciences
pneumonia, 12% show multiple mottling and ground-glass opacity and 1% patient show
pneumothorax. 16% identify with acute respiratory distress syndrome amongst them 10%
patients worsen a short period of time and died of multiple organ failure, it more likely affect
older males with comorbidities. Few patients died with the MuLBSTA score, it is an early
warning model foresee mortality in viral pneumonia. Research are in process to investigate
applicability of the MuLBSTA score in foresee the risk of mortality in 2019-nCoV
infection.[22]
Huge population infected most are men (70%) and have hypertension , cardiovascular and
diabetes, and symptoms observe are Dyspnoea , sputum production, lymphopenia also
pneumonia with abnormal findings on chest CT. some Complications are acute respiratory
distress syndrome, RNAaemia, acute cardiac injuryand secondary infections patients were
admitted to an ICU and 10% died.in comparative with NON-ICU patients higher plasma
levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNFα observe in ICU patients. A
batch or collection of severe respiratory illness occur by novel 2019-nCoV infection.[23]
Patients may show normal or less white blood cell counts, lymphopenia, or
thrombocytopenia, with prolonged activated thromboplastin time and rise C-reactive protein
level. In short, patients suffering from fever and upper respiratory tract symptoms with
lymphopenia or leukopenia should be suspect mostly in patients with Wuhan disclosure or
close contact history.[21,22,23].
Diagnosis of COVID-19
Early stages symptoms are non – specific, some common respiratory disorders from different
diagnosis might be infectious or non -infectious are Adenovirus, Influenza, Human
metapneumovirus (HmPV), Parainfluenza, Rhenovirus and Respiratory syncytial
virus(RSV).[2]
Clinical diagnosis is done by Radiology and CT imaging findings, first the
clinical diagnostic workflow should be there to confirm Wuhan exposure history or close
contact , connection with people from Wuhan or confirmed patients from last few weeks.
WHO recommends and collect samples of upper and lower respiratory tracts accomplish
through expectorated sputum, broncho alveolar lavage, or endotracheal aspirate then samples
are estimate for viral RNA by using polymerase chain reaction (PCR). If positive test observe
then test is repeat for re- verification, if test is negative with strong clinical suspicion also
warrants for repeat testing for accurate results and confirmation.[24]
U.S. CDC set rules and
criteria for persons under investigation (PUI).[2]
in (PUI) instant prevention and infection
www.wjpps.com Vol 9, Issue 6, 2020.
679
Suresh et al. World Journal of Pharmacy and Pharmaceutical Sciences
control measures are taken. Various Epidemiological factors are used for testing purpose.[24]
there are many patients have no evidence and unknown exposure history rising due to rapid
spread of virus. The National Health Commission of China start Diagnosis and Treatment
Program of 2019 New Coronavirus Pneumonia (trial sixth version) (fig. 3) with the
guidelines given by (WHO) world health organization on (SARS) and (MERS),[27,28]
and
arranged experts to analyze , judge , and summarize the initial work of treatment and modify
it.[26]
MERS-CoV also extracted from the patient and the camel. The overall genome
sequences of the two isolates are similar mortal case of human MERS-CoV infection was
transfer through close contact with an infected camel.[27]
If patient have exposure history and
clinical conditions is consider as a suspected case, if no exposure history but have 2or 3
clinical conditions then it is conclude a suspected patient(fig 2).on the basis of (fifth trial
version).[29]
The clinical diagnosis of COVID-19 infection confirmation and manifest are
chest CT findings of viral pneumonia. though, WHO not believe or accept CT without RT-
PCR evidence till February, 17, 2020.[30]
The clinical diagnosis term is removed in currently
published Diagnosis and Treatment Program of 2019 New Coronavirus Pneumonia (trial
sixth version).[28]
the last examination or diagnosis of COVID-19 is important this is later
confirm by positive real-time polymerase chain reaction ( RT-PCR ) assay for COVID-19
with the help of respiratory and blood samples or by viral gene sequencing of respiratory or
blood samples which are greatly equivalent to COVID-19. On the basis of clinical
symptoms confirmed patients are separated in to mild, moderate, severe, and acute or critical
types (table 3).[28,31,32]
Table 3: Standard for clinical severity of conform cases of COVID-19 coronavirus
disease 2019 pneumonia, data from.[28,31,32]
Types Findings
Mild Mild clinical symptoms [fever<37°C(quelled without treatment) with or
without cough no dyspnea, no grasping , no chronic disease], no imaging
findings of pneumonia
Moderate Fever, respiratory symptoms and imaging findings of pneumonia
Severe Meet any of following: Meet respiratory distress, RR≥30times/min
Spo2 <93% at rest
Pao2/ Fio2≤ 300 mmHg
Critical Meet any of following : Respiratory failure need mechanical assistance
Shock
―Extra pulmonary‖organ failure, intensive care unit is needed
Patients showing rapid progression (>50%) on CT imaging with in 24-48
hrs should mange as severe(trail sixth edition)
www.wjpps.com Vol 9, Issue 6, 2020.
680
Suresh et al. World Journal of Pharmacy and Pharmaceutical Sciences
Fig. 2: coronavirus case by Chinese Health Commission.
Pathophisology
Coronaviruses are sure positive strand RNA infections that cause malady in people, and
residential and buddy creatures. CoVs are encompassed /enveloped, positive-stranded RNA
infections with nucleocapsid. They are generally famous for causing extreme intense
respiratory disorder (SARS) episodes in 2002–2003[2,33]
All coronaviruses follow a similar
essential system of replication. All coronaviruses encode 15 or 16 replicase related proteins, 4
or 5 basic proteins and 1–8 gathering explicit or adornment proteins. A considerable lot of the
replicase proteins are gathered into replication hardware in twofold film vesicles (DMVs) and
on a reticular system of layers that are gotten from the endoplasmic reticulum. In numerous
coronavirus contaminations, ailment seriousness increments during infection leeway,
proposing that the host invulnerable reaction is both defensive and pathogenic. Moreover,
hindrance of explicit parts of the resistant reaction brings about less serious infection and less
tissue obliteration, without reducing the energy of infection leeway. Like all fruitful
infections, coronaviruses have advanced both uninvolved and dynamic instruments to avoid
the interferon reaction. Replication in DMVs may add to uninvolved avoidance of the natural
resistant reaction by making twofold stranded RNA out of reach to cell sensors.[33]
Coronaviruses picked up unmistakable quality during the extreme intense respiratory disorder
(SARS) episodes of 2002–2003.[34]
The viral film contains the transmembrane (M)
www.wjpps.com Vol 9, Issue 6, 2020.
681
Suresh et al. World Journal of Pharmacy and Pharmaceutical Sciences
glycoprotein, the spike (S) glycoprotein and the envelope (E) protein, and encompasses a
cluttered or adaptable, most likely helical, nucleocapsid. The viral film is surprisingly thick,
most likely in light of the fact that the carboxy-terminal locale of the M protein shapes an
extra inside layer, as uncovered by cryo-electron tomography. Coronaviruses are isolated into
three gatherings, and further subdivided into subgroups, dependent on serologic, and all the
more as of late on hereditary, examinations. With the ID of all the more indirectly related
infections, the scientific classification of these infections is probably going to experience
further changes.[35,36]
For tending to pathogenetic components of SARS-CoV-2, its viral
structure, and genome must be contemplations. In CoVs, the genomic structure is composed
in a +ssRNA of roughly 30 kb long — the biggest known RNA infections — and with a 5′-
top structure and 3′-poly-A tail. Beginning from the viral RNA, the combination of
polyprotein 1a/1ab (pp1a/pp1ab) in the host is figured it out. The interpretation works
through the replication-translation complex (RCT) sorted out in twofold layer vesicles and by
means of the combination of subgenomic RNAs (sgRNAs) arrangements. Of note, translation
end happens at interpretation administrative successions, situated between the alleged open
understanding casings (ORFs) that fill in as layouts for the creation of subgenomic mRNAs.
In the atypical CoV genome, in any event six ORFs can be available. Among these, a
frameshift somewhere in the range of ORF1a and ORF1b guides the creation of both pp1a
and pp1ab polypeptides that are handled by virally encoded.
Fig. 3: Arrangement /framework of coronavirus genome and virion.
a. Schematic outline of delegate genomes from each of the coronavirus gatherings. Around
the initial 66% of the 26–32 Kb, positive-sense RNA genome encodes a huge polyprotein
(ORF1a/b; green) that is proteolytically separated to create 15 or 16 non-auxiliary
www.wjpps.com Vol 9, Issue 6, 2020.
682
Suresh et al. World Journal of Pharmacy and Pharmaceutical Sciences
proteins (nsps; nsps for extreme intense respiratory disorder coronavirus (SARS-CoV) are
outlined). The 3′-end third of the genome encodes four basic proteins — spike (S), film
(M), envelope (E) and nucleocapsid (N) (all appeared in blue) — alongside a lot of extra
proteins that are novel to every infection species (appeared in red). Some gathering 2
coronaviruses express an extra basic protein, haemagglutinin -esterase (not appeared).
b. Schematic outline of the coronavirus virion. 2′OMT, ribose-2′-O-methyltransferase;
ExoN, 3′→5′ exonuclease; Hel, helicase; IBV, contamination bronchitis infection;
NendoU , uridylate -explicit endoribonuclease; RDRP, RNA-subordinate RNA
polymerase; ssRBP, single-stranded RNA restricting protein; ssRNA, single-stranded
RNA; TGEV, transmissible gastroenteritis infection.
Chymotrypsin-like protease (3CLpro) or fundamental protease (Mpro), just as a couple of
papain-like proteases for delivering 16 non-basic proteins (nsps). Aside from ORF1a and
ORF1b, different ORFs encode for basic proteins, including spike, film, envelope, and
nucleocapsid proteins[37]
A subset of gathering 2 coronaviruses encode an extra
haemagglutinin - esterase (HE) protein (Fig 3). The HE protein, which might be engaged
with infection passage or departure, isn't required for replication, yet seems, by all accounts,
to be significant for contamination of the regular host.[38]
Pathophysiology and
destructiveness mechanisms of CoVs, and consequently likewise of SARS-CoV-2 have
connections to the capacity of the nsps and auxiliary proteins. For example, inquire about
underlined that nsp can hinder the host natural insusceptible reaction. Among elements of
basic proteins, the envelope has a vital job in infection pathogenicity as it advances viral get
together and discharge. Nonetheless, a considerable lot of these highlights (e.g., those of nsp
2, and 11) have not yet been portrayed. Among the auxiliary components of CoVs, there are
the spike glycoproteins made out of two subunits (S1 and S2). Homotrimers of S proteins
form the spikes on the viral surface, controlling the connection to have receptors.[39,40]
Of note, in SARS-CoV-2, the S2 subunit — containing a combination peptide, a
transmembrane area, and cytoplasmic space — is profoundly rationed. Therefore, it could be
an objective for antiviral (hostile to S2) mixes. Despite what might be expected, the spike
receptor-restricting area presents just a 40% amino corrosive character with different SARS-
CoVs. Other auxiliary components on which research should fundamentally center are the
ORF3b that has no homology with that of SARS-CoVs and a discharged protein (encoded by
ORF8), which is basically not quite the same as those of SARS-CoV[41,33]
In global quality
banks, for example, GenBank, specialists have distributed a few Sars-CoV-2 quality
arrangements. This quality mapping is of key significance permitting scientists to follow the
phylogenetic tree of the infection and, most importantly, the acknowledgment of strains that
www.wjpps.com Vol 9, Issue 6, 2020.
683
Suresh et al. World Journal of Pharmacy and Pharmaceutical Sciences
contrast as indicated by the changes. As indicated by late research, a spike transformation,
which likely happened in late November 2019, activated bouncing to people. Specifically,
Angeletti et al. looked at the Sars-Cov-2 quality grouping with that of Sars-CoV. They
examined the transmembrane helical fragments in the ORF1ab encoded 2 (nsp2) and nsp3
and found that position 723 presents a serine rather than a glycine buildup, while the position
1010 is involved by proline rather than isoleucine. The matter of viral transformations is key
for clarifying potential infection backslides.[41]
The matter of viral changes is key for clarifying potential infection backslides. Research will
be expected to decide the basic attributes of SARS-COV-2 that underlie the pathogenetic
systems. Contrasted with SARS, for instance, starting clinical information show less extra
respiratory association, albeit because of the absence of broad information, it is beyond the
realm of imagination to expect to draw authoritative clinical data. The pathogenic instrument
that produces pneumonia is by all accounts especially mind boggling. Clinical and preclinical
research should clarify numerous perspectives that underlie the specific clinical introductions
of the sickness. The information so far accessible appear to demonstrate that the viral
contamination is equipped for delivering an over the top resistant response in the host. Now
and again, a response happens which all in all is named a 'cytokine storm'. The impact is
broad tissue harm. The hero of this tempest is interleukin 6 (IL-6). IL-6 is created by enacted
leukocytes and follows up on countless cells and tissues. It can advance the separation of B
lymphocytes, advances the development of certain classes of cells, and restrains the
development of others. It additionally invigorates the creation of intense stage proteins and
assumes a significant job in thermoregulation, in bone upkeep and in the usefulness of the
focal sensory system. Despite the fact that the fundamental pretended by IL-6 is expert
provocative, it can likewise have mitigating impacts. Thus, IL-6 increments during fiery
ailments, contaminations, immune system issue, cardiovascular infections and a few kinds of
malignancy. It is likewise involved into the pathogenesis of the cytokine discharge disorder
(CRS) that is an intense fundamental fiery disorder described by fever and various organ
brokenness[2,40,41,42]
Mechanism/System of coronavirus replication and translation
The N protein is significant for encapsidation of viral RNA and goes about as an interferon
(IFN) rival (see underneath). Moreover, it causes upregulation of FGL2, a prothrombinase
that adds to lethal hepatic sickness in mice that are contaminated with MHV-3.[43]
and that
www.wjpps.com Vol 9, Issue 6, 2020.
684
Suresh et al. World Journal of Pharmacy and Pharmaceutical Sciences
alters changing development factor-β (TGFβ) motioning in SARS-CoV-tainted cells.[44]
The
E proteins are little indispensable layer proteins with jobs in infection morphogenesis, get
together and maturing. Without E proteins, infection discharge is restrained totally (on
account of transmissible gastroenteritis infection (TGEV)) or somewhat (on account of
SARS-CoV and MHV).[45,46,47]
The E protein likewise has particle channel action, which is
required for ideal infection replication.[48,49]
Scattered between and in these auxiliary qualities are one to eight qualities that encode
adornment proteins, contingent upon the infection strain. These show no grouping similitude
with other viral or cell proteins and are not required for infection replication in refined
cells.[50,51,52]
In any case, they are moderated in infection species secluded at various
occasions and regions (for instance, for SARS-CoV).[53]
which recommends that these
proteins have a significant job in replication in the regular host. A few accessory proteins are
virion-related[54,55,56,57]
despite the fact that whether these proteins are genuinely basic is
disputable.[58]
The genes that encode non-replicase proteins are expressed from a set of
'nested' subgenomic mRNAs that have common 3′ ends and a common leader that is encoded
at the 5′ end of genomic RNA. Proteins are produced generally only from the first ORF of
subgenomic mRNAs, which are produced during minus strand RNA synthesis. Transcription
termination and subsequent acquisition of a leader RNA occurs at transcription regulatory
sequences (TRS), located between ORFs. These minus strand subgenomic RNAs serve as
templates for the production of subgenomic mRNAs (Fig. 4), an efficient process that results
in a high ratio of subgenomic mRNA to minus strand subgenomic RNA.[59]
Fig.4: System / Mechanism of replication and transcription of COVID-19.[59]
www.wjpps.com Vol 9, Issue 6, 2020.
685
Suresh et al. World Journal of Pharmacy and Pharmaceutical Sciences
a) Following section into the cell and uncoating, the positive sense RNA genome is meant
produce replicase proteins from open perusing outline 1a/b (ORF1a/b). These proteins
utilize the genome as a format to produce full-length negative sense RNAs, which in this
manner fill in as layouts in creating extra full-length genomes.
b) Coronavirus mRNAs all contain a typical 5′ pioneer arrangement intertwined to
downstream quality successions. These pioneers are included by an intermittent union of
less sense subgenomic RNAs utilizing genome RNA as a format (looked into in Ref. 29).
Subgenomic RNAs are started at the 3′ end of the genome and continue until they
experience one of the transcriptional administrative groupings (TRS; red) that dwell
upstream of most open-understanding casings.
c) Through base-pairing collaborations, the early transcript is moved to the corresponding
pioneer TRS (light red).
d) and translation proceeds through the 5′ end of the genome,
e) These subgenomic RNAs at that point fill in as formats for viral mRNA creation.
Treatment of COVID-19
Current remedies/Medication
Given the absence of successful antiviral treatment against COVID-19, current medicines for
the most part centered around symptomatic and respiratory help as indicated by the Diagnosis
and Treatment of Pneumonia Caused by COVID-19 (refreshed to form 6) gave by National
Health Commission of the People's Republic of China.[60]
About all patients acknowledged
oxygen treatment, and WHO suggested extracorporeal membrane oxygenation (ECMO) to
patients with obstinate hypoxemia.[61]
Salvage treatment with gaining strength plasma and
immunoglobulin G[62,63]
are conveyed to some basic cases as indicated by their conditions.
Antiviral medication
In view of the experience of battling the pandemic SARS-CoV and MERS-CoV beforehand,
we may get familiar with certain exercises for some treatment systems against coronavirus.[64]
Antiviral medications and foundational corticosteroid treatment usually utilized in clinical
practice already, including neuraminidase inhibitors (oseltamivir, peramivir, zanamivir, and
so forth), ganciclovir, acyclovir, and ribavirin, just as methylprednisolone[65,66]
for flu
infection, are invalid for COVID-19 and not prescribed. Remdesivir (GS-5734) is a 1′-cyano-
subbed adenosine nucleotide simple prodrug and shows expansive range antiviral movement
against a few RNA infections. In light of the information gathered from in vitro cell line and
www.wjpps.com Vol 9, Issue 6, 2020.
686
Suresh et al. World Journal of Pharmacy and Pharmaceutical Sciences
mouse model, remdesivir could meddle with the NSP12 polymerase even in the setting of
unblemished ExoN editing action.[67]
Remdesivir has been accounted for to treat the primary
US instance of COVID-19 effectively.[68]
Chloroquine is a repurposed medicate with
extraordinary potential to treat COVID-19. Chloroquine has been utilized to treat intestinal
sickness for a long time.[69]
with a system that isn't surely known against some popular
contaminations. A few potential systems are researched: Chloroquine can restrain pH-
subordinate strides of the replication of a few infections,[70]
with a strong impact on SARS-
CoV contamination and spread.[71]
Besides, chloroquine has immunomodulatory impacts, stifling the creation/arrival or release
of TNF-α and IL-6. It additionally functions as a novel class of autophagy inhibitor,[72]
which
may meddle with viral contamination and replication. A few examinations have discovered
that chloroquine meddled with the glycosylation of cell receptors of SARS-CoV[71]
what's
more, worked at both section and at post-passage phases of the COVID-19 contamination in
Vero E6 cells.[73]
A combo of remdesivir and chloroquine was demonstrated to viably restrain
the as of late rose or inhibit SARS-CoV-2 in vitro. Researchers recently affirmed that the
protease inhibitors lopinavir and ritonavir, used to treat disease with human
immunodeficiency infection (HIV),[74]
could improve the result of MERS-CoV[75]
and SARS-
CoV[76]
patients. It has announced that β-coronavirus viral heaps of a COVID-19 patient in
Korea fundamentally diminished after lopinavir/ritonavir (Kaletra®, AbbVie, North Chicago,
IL, USA) treatment.[77]
Moreover, clinicians joined Chinese and Western medication
treatment including lopinavir/ritonavir (Kaletra®), arbidol, and Shufeng Jiedu Capsule
(SFJDC, a conventional Chinese medication) and increased huge improvement in pneumonia
related indications in Shanghai Public Health Clinical Center, China.[78]
The other antiviral
medications incorporate nitazoxanide, favipiravir, nafamostat, etc.[63]
Neuraminidase inhibitors
Neuraminidase inhibitors are shown in the administration of influenza.[79]
In an examination
on conceivable MERS-CoV cases in Paris from 2013 to 2016, a sum of 35 patients got
oseltamivir (37.6%). In patients positive for flu infection (n = 25), 52% (n = 13) got
oseltamivir and it was reasoned that observational oseltamivir can be begun in presumed
MERS-CoV cases.[80]
Many different investigations likewise assessed oseltamivir in MERS-
CoV.[81]
Oseltamivir was additionally utilized in the administration of 2019-nCoV;
www.wjpps.com Vol 9, Issue 6, 2020.
687
Suresh et al. World Journal of Pharmacy and Pharmaceutical Sciences
notwithstanding, unequivocal proof of adequacy is uncertain in view of absence of
appropriate benchmark group in the studies.[82]
Others medications
Other treatment choices, which are either utilized once in a while or in test state, are SiRNA,
tumor rot factor-alpha inhibitors, killing antibodies, pentoxifylline, and so on., However, the
degree of proof is very poor and subsequently not prescribed for routine consideration.[83]
Recent progress in the treatment of COVID-19
Baricitinib
The SARSCoV and the 2019nCoV both enters host cells through ACE2 receptormediated
entry, especially through AT2 cells present in lungs.[84]
Downstream signaling of this receptor
mediates the endocytosis process, and AP2-associated protein kinase 1 (AAK1) plays a major
role in this process. Thus, AAK1 represents an important target. Richardson et al., 2020
evaluated 378 ligands, of which 47 were already approved for use in other conditions. Among
these ligands, six inhibited AAK1 with high affinity. Considering the side effect profile, they
found janus kinase inhibitor baricitinib to be the most important agent. In addition to AAK1,
baricitinib also binds to another endocytosis regulator protein (cyclin G-associated kinase).
Thus, the authors suggest that baricitinib can be evaluated in the in vitro conditions as well as
in the clinical trial settings for 2019-nCoV.[85,86]
Epidemiology
Cases across World Wide
At present (12 May, 2020) coronavirus cases are 4.18 million, Deaths: 286K, Recovered:
1.46 million. As Graph-1
Graph-1
www.wjpps.com Vol 9, Issue 6, 2020.
688
Suresh et al. World Journal of Pharmacy and Pharmaceutical Sciences
The Impacts of Coronavirus on Economy in India and beyond
The impact of coronavirus is probably going to be seen long after clinical science offers a fix
or possibly an immunization or vaccine. Barclays gauges, that India's forceful 21-day
lockdown could bring the nation's development down to 2.5% from the 4.5% it had before
assessed. A 2019 joint report from the World Health Organization (WHO) and the World
Bank evaluates the effect of such a pandemic at 2.2 percent to 4.8 percent of worldwide GDP
(US$3 trillion). That was well before the world knew about Covid-19. As Prime Minister
Narendra Modi said in his location to the country when he reported a 21-day lockdown, if
this pandemic isn't contained, it could hinder us by decades.
Ben Bernanke, previous administrator of the US Federal Reserve, is significantly more
hopeful. In a TV talk with, Bernanke stated: If there's not all that much harm done to the
workforce, to the organizations during the shutdown time frame, anyway long that perhaps, at
that point we could see a genuinely speedy bounce back.[88]
COVID-19 could influence the
worldwide economy in three primary manners: by legitimately influencing creation, by
making store network and market disturbance (by directly affecting production, by creating
supply chain and market disruption, and by its financial impact), and by its budgetary effect
on firms and money related markets. Nonetheless, an extraordinary arrangement relies upon
the open's response to the malady.
COVID-19 could influence the worldwide economy through three channels
1. Direct impact on production: Chinese creation has just been significantly influenced by
the shutdown in Hubei territory and different territories. Some different nations are
additionally starting to feel an immediate effect as their specialists set up comparable
measures. The stoppage in China has impacts on exporters to China. China's biggest
wellsprings of imports are Korea, Japan, and other Asian nations, as indicated by the
World Bank [89]. Thus, even without new flare-ups of the malady, these zones will
probably encounter moderate development in the primary portion of 2020.
2. Market and supply chain disruption: Many manufacturing firms rely on imported
intermediate inputs from China and other countries affected by the disease. Many
companies rely on sales to meet the financial goals. The slowdown in financial as well as
economic activity and restrictions in transportation in affected countries will likely have
an impact on the production and profitability of specific global companies, mainly in
manufacturing and in raw materials used in manufacturing. For companies that depend on
www.wjpps.com Vol 9, Issue 6, 2020.
689
Suresh et al. World Journal of Pharmacy and Pharmaceutical Sciences
on intermediate goods from affected regions, and that are not able to easily switch
sourcing, the size of the impact may depend on how quickly the outbreak fades. Small
and medium-sized firms may have more difficulty surviving the disruption. Businesses
knotted to travel and tourism are facing losses that are likely not recoverable.
3. Financial impact on firms and financial markets: Impermanent interruptions of
sources of info or potentially creation may pressure a few firms, especially those with
deficient liquidity. Brokers in monetary markets could conceivably effectively foresee or
comprehend which firms may be powerless. The subsequent ascent in hazard may
uncover that at least one key monetary market players have taken speculation places that
are unrewarding under current conditions, further debilitating trust in money related
instruments and markets. A potential (likely low-likelihood) occasion would be a huge
money related market disturbance as members become worried about counterparty
hazard. A to some degree more probable chance is a critical decrease in value markets
and corporate security markets, with financial specialists liking to hold government
protections (especially US treasuries) due to the vulnerability made by the pandemic.
MSME problems under lockdown
Be that as it may, regardless of whether worldwide economies bob back sooner than
anticipated, Indian MSMEs are probably going to follow through on a significant expense.
These organizations are too little to even consider having a sufficient pad to last through a
pandemic like this one. Add to this the way that a considerable lot of these organizations have
been approached to down shades or abridge tasks while as yet paying workers and that is
separated from meeting costs for expenses, power, and different utilities.
The Prime Minister has reported the formation of a financial team to propose a few stages to
facilitate the circumstance.
This is as essential as reinforcing the nation's medicinal services framework. Accessible
information show that MSMEs utilize as much as 110 million individuals; requesting that
organizations continue paying during a drawn out lockdown is anything but an economical
arrangement in the medium-to long haul. Media reports state that MSME delegates have
spoke to the administration for solid action. This incorporates charge concessions, simple
access to credit, GST discounts, and repayment or concession for wage-ensure.[88]
Today
announces the 10% Total GDP of India given to the people.
www.wjpps.com Vol 9, Issue 6, 2020.
690
Suresh et al. World Journal of Pharmacy and Pharmaceutical Sciences
REFERENCES
1. World Health Organization. Household transmission investigation protocol for
coronavirus disease 201 ( COVID-1 ) . World Health Organization; 2020.
2. Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, Evaluation and
Treatment Coronavirus (COVID-19). InStat Pearls [Internet] Stat Pearls Publishing,
2020; 3: 8.
3. . Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N, Bi Y.
Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for
virus origins and receptor binding. The Lancet, 2020; 22,395(10224): 565-74.
4. ,Wang Q, Wang YH, Ma JC et al. Description of the first strain of 2019-nCoV, C-Tan-
nCoV Wuhan Strain — National Pathogen Resource Center, China, 2020
5. Millet JK, Whittaker GR. Host cell proteases: Critical determinants of coronavirus
tropism and pathogenesis. Virus research, 2015; 16,202: 120-34.
6. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan
JL, Luzuriaga K, Greenough TC, Choe H. Angiotensin-converting enzyme 2 is a
functional receptor for the SARS coronavirus. Nature, 2003; 426(6965): 450-4.
7. Kirchdoerfer RN, Cottrell CA, Wang N, Pallesen J, Yassine HM, Turner HL, Corbett KS,
Graham BS, McLellan JS, Ward AB. Pre-fusion structure of a human coronavirus spike
protein. Nature, 2016; 531(7592): 118-21.
8. Xu X, Chen P, Wang J, Feng J, Zhou H, Li X, Zhong W, Hao P. Evolution of the novel
coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk
of human transmission. Science China Life Sciences, 2020; 63(3): 457-60.
9. Gorbalenya AE. Severe acute respiratory syndrome-related coronavirus–The species and
its viruses, a statement of the Coronavirus Study Group. BioRxiv, 2020; 1.
10. World Health Organization. Director-General's remarks at the media briefing on 2019-
nCoV on, 2020; 02: 21. https://www. who. int/dg/speeches/detail/who-directorgeneral-s-
remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020. 2020.
11. Lam TT, Shum MH, Zhu HC, Tong YG, Ni XB, Liao YS, Wei W, Cheung WY, Li WJ,
Li LF,Leung GM. Identification of 2019-nCoV related coronaviruses in Malayan
pangolins in southern China. BioRxiv, 2020; 1: 1.
12. Zhang L, Shen FM, Chen F, Lin Z. Origin and evolution of the 2019 novel coronavirus.
Clinical Infectious Diseases, 2020; 2: 3.
www.wjpps.com Vol 9, Issue 6, 2020.
691
Suresh et al. World Journal of Pharmacy and Pharmaceutical Sciences
13. Hu D, Zhu C, Ai L, He T, Wang Y, Ye F, Yang L, Ding C, Zhu X, Lv R, Zhu J. Genomic
characterization and infectivity of a novel SARS-like coronavirus in Chinese bats.
Emerging microbes & infections, 2018; 1,7(1): 1-0.
14. General Office of National Health Committee. Office of state administration of
traditional Chinese medicine. Notice on the issuance of a programme for the diagnosis
and treatment of novel coronavirus (2019-nCoV) infected pneumonia (trial fifth edition),
2020; 02: 26.
15. Kanne JP. Chest CT findings in 2019 novel coronavirus (2019-nCoV) infections from
Wuhan, China: key points for the radiologist. Radiology, 2020; 4: 200241.
16. Pan Y, Guan H. Imaging changes in patients with 2019-nCov.
17. Ng MY, Lee EY, Yang J, Yang F, Li X, Wang H, Lui MM, Lo CS, Leung B, Khong PL,
Hui CK. Imaging profile of the COVID-19 infection: radiologic findings and literature
review. Radiology: Cardiothoracic Imaging, 2020; 13.2(1): e200034.
18. Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, Cooley LA, Dean
NC, Fine MJ, Flanders SA, Griffin MR. Diagnosis and treatment of adults with
community-acquired pneumonia. An official clinical practice guideline of the American
Thoracic Society and Infectious Diseases Society of America. American journal of
respiratory and critical care medicine, 2019; 1.200(7): e45-67.
19. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DS, Du
B. Clinical characteristics of novel coronavirus infection in China. medRxiv, 2019.
20. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y,
Zhao Y. Clinical characteristics of 138 hospitalized patients with 2019 novel
coronavirus–infected pneumonia in Wuhan, China. Jama, 2020; 2: 7.
21. Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, Xing F, Liu J, Yip CC, Poon RW,
Tsoi HW. A familial cluster of pneumonia associated with the 2019 novel coronavirus
indicating person-to-person transmission: a study of a family cluster. The Lancet, 2020;
15.395(10223): 514-23.
22. Chen L. Han. Yang F, Zhang tJ, 2001.
23. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z.
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The
Lancet, 2020; 15.395(10223): 497-506.
24. Hassan SA, Sheikh FN, Jamal S, Ezeh JK, Akhtar A. Coronavirus (COVID-19): A
Review of Clinical Features, Diagnosis, and Treatment.
www.wjpps.com Vol 9, Issue 6, 2020.
692
Suresh et al. World Journal of Pharmacy and Pharmaceutical Sciences
25. World Health Organization. Clinical management of severe acute respiratory infection
when novel coronavirus (2019-nCoV) infection is suspected, 2019.
At https://www.who.int/csr/disease/coronavirus_infections/InterimGuidance_ClinicalMan
agement_NovelCoronavirus_11Feb13u.pdf?ua=1&ua=1. Accessed February 11, 2020.
26. World Health Organization. WHO guidelines for the global surveillance of severe acute
respiratory syndrome (SARS). 2004.
at https://www.who.int/csr/resources/publications/WHO_CDS_CSR_ARO_2004_1.pdf?u
a=1. Published January, 2004.
27. Azhar EI, El-Kafrawy SA, Farraj SA, Hassan AM, Al-Saeed MS, Hashem AM, Madani
TA. Evidence for camel-to-human transmission of MERS coronavirus. New England
Journal of Medicine, 2014; 26.370(26): 2499-505.
28. General Office of National Health Committee. Office of State Administration of
Traditional Chinese Medicine. Notice on the issuance of a program for the diagnosis and
treatment of novel coronavirus (2019-nCoV) infected pneumonia (trial sixth edition)
(2020-02-19) [EB/OL]. http://yzs.satcm.gov.cn/zhengcewenjian/2020-02-19/13221.html]
29. General Office of National Health Committee. Office of state administration of traditional
Chinese medicine. Notice on the issuance of a programme for the diagnosis and treatment
of novel coronavirus (2019-nCoV) infected pneumonia (trial fifth edition), 2020; 02: 26.
[EB/OL]. http://bgs.satcm.gov.cn/zhengcewenjian/2020-02-06/12847.html
30. World Health Organization. Coronavirus Disease 2019(COVID-19): situation report—28.
2020. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200217-
sitrep-28-covid-19.pdf?sfvrsn=a19cf2ad_2. Published February, 2020; 18: 20.
31. World Health Organization. Home care for patients with suspected novel coronavirus
(nCoV) infection presenting with mild symptoms and management of contacts
[EB/OL]. https://www.who.int/publications-detail/home-care-for-patients-with-suspected-
novel-coronavirus-(ncov)-infection-presenting-with-mild-symptoms-and-management-of-
contacts. Published January, 2020; 20: 11.
32. Zu ZY, Jiang MD, Xu PP, Chen W, Ni QQ, Lu GM, Zhang LJ. Coronavirus disease 2019
(COVID-19): A perspective from China. Radiology, 2020; 21: 200490.
33. Perlman S, Netland J. Coronaviruses post-SARS: update on replication and pathogenesis.
Nature reviews microbiology, 2009; 7(6): 439-50.
34. Peiris JS, Guan Y, Yuen KY. Severe acute respiratory syndrome. Nature medicine, 2004;
10(12): S88-97.
www.wjpps.com Vol 9, Issue 6, 2020.
693
Suresh et al. World Journal of Pharmacy and Pharmaceutical Sciences
35. Bárcena M, Oostergetel GT, Bartelink W, Faas FG, Verkleij A, Rottier PJ, Koster AJ,
Bosch BJ. Cryo-electron tomography of mouse hepatitis virus: insights into the structure
of the coronavirion. Proceedings of the National Academy of Sciences, 2009; 13.106(2):
582-7.
36. Neuman BW, Adair BD, Yoshioka C, Quispe JD, Orca G, Kuhn P, Milligan RA, Yeager
M, Buchmeier MJ. Supramolecular architecture of severe acute respiratory syndrome
coronavirus revealed by electron cryomicroscopy. Journal of virology, 2006; 15.80(16):
7918-28.
37. Masters PS. The molecular biology of coronaviruses. Advances in virus research, 2006;
1.66: 193-292.
38. Lissenberg A, Vrolijk MM, Van Vliet AL, Langereis MA, de Groot-Mijnes JD, Rottier
PJ, de Groot RJ. Luxury at a cost? Recombinant mouse hepatitis viruses expressing the
accessory hemagglutinin esterase protein display reduced fitness in vitro. Journal of
virology, 2005; 15.79(24): 15054-63.
39. Lei J, Kusov Y, Hilgenfeld R. Nsp3 of coronaviruses: Structures and functions of a large
multi-domain protein. Antiviral research, 2018; 1.149: 58-74.
40. Song W, Gui M, Wang X, Xiang Y. Cryo-EM structure of the SARS coronavirus spike
glycoprotein in complex with its host cell receptor ACE2. PLoS pathogens, 2018;
13.14(8): e1007236.
41. Angeletti S, Benvenuto D, Bianchi M, Giovanetti M, Pascarella S, Ciccozzi M. COVID-
2019: The role of the nsp2 and nsp3 in its pathogenesis. J. Med. Virol, 2020; 2: 21.
42. Tian S, Hu W, Niu L, Liu H, Xu H, Xiao SY. Pulmonary pathology of early phase 2019
novel coronavirus (COVID-19) pneumonia in two patients with lung cancer. Journal of
Thoracic Oncology, 2020; 2: 28.
43. Ning Q, Lakatoo S, Liu M, Yang W, Wang Z, Phillips MJ, Levy GA. Induction of
prothrombinase fgl2 by the nucleocapsid protein of virulent mouse hepatitis virus is
dependent on host hepatic nuclear factor-4α. Journal of Biological Chemistry, 2003;
2.278(18): 15541-9.
44. Zhao X, Nicholls JM, Chen YG. Severe acute respiratory syndrome-associated
coronavirus nucleocapsid protein interacts with Smad3 and modulates transforming
growth factor-β signaling. Journal of Biological Chemistry, 2008; 8.283(6): 3272-80.
45. DeDiego ML, Álvarez E, Almazán F, Rejas MT, Lamirande E, Roberts A, Shieh WJ,
Zaki SR, Subbarao K, Enjuanes L. A severe acute respiratory syndrome coronavirus that
www.wjpps.com Vol 9, Issue 6, 2020.
694
Suresh et al. World Journal of Pharmacy and Pharmaceutical Sciences
lacks the E gene is attenuated in vitro and in vivo. Journal of virology, 2007; 15.81(4):
1701-13.
46. Kuo L, Masters PS. The small envelope protein E is not essential for murine coronavirus
replication. Journal of virology, 2003; 15.77(8): 4597-608.
47. Ortego J, Ceriani JE, Patiño C, Plana J, Enjuanes L. Absence of E protein arrests
transmissible gastroenteritis coronavirus maturation in the secretory pathway. Virology,
2007; 25.368(2): 296-308.
48. Madan V, de Jesús García M, Sanz MA, Carrasco L. Viroporin activity of murine
hepatitis virus E protein. FEBS letters, 2005; 4.579(17): 3607-12.
49. Wilson L, Mckinlay C, Gage P, Ewart G. SARS coronavirus E protein forms cation-
selective ion channels. Virology, 2004; 5.330(1): 322-31.
50. Yount B, Roberts RS, Sims AC, Deming D, Frieman MB, Sparks J, Denison MR, Davis
N, Baric RS. Severe acute respiratory syndrome coronavirus group-specific open reading
frames encode nonessential functions for replication in cell cultures and mice. Journal of
virology, 2005; 15.79(23): 14909-22.
51. Ontiveros E, Kuo L, Masters PS, Perlman S. Inactivation of expression of gene 4 of
mouse hepatitis virus strain JHM does not affect virulence in the murine CNS. Virology,
2001; 25.289(2): 230-8.
52. de Haan CA, Masters PS, Shen X, Weiss S, Rottier PJ. The group-specific murine
coronavirus genes are not essential, but their deletion, by reverse genetics, is attenuating
in the natural host. Virology, 2002; 25.296(1): 177-89.
53. Li W, Shi Z, Yu M, Ren W, Smith C, Epstein JH, Wang H, Crameri G, Hu Z, Zhang H,
Zhang J. Bats are natural reservoirs of SARS-like coronaviruses. Science, 2005;
28.310(5748): 676-9.
54. Fischer F, Peng D, Hingley ST, Weiss SR, Masters PS. The internal open reading frame
within the nucleocapsid gene of mouse hepatitis virus encodes a structural protein that is
not essential for viral replication. Journal of virology, 1997; 1.71(2): 996-1003.
55. Huang C, Peters CJ, Makino S. Severe acute respiratory syndrome coronavirus accessory
protein 6 is a virion-associated protein and is released from 6 protein-expressing cells.
Journal of virology, 2007; 15.81(10): 5423-6.
56. Ito N, Mossel EC, Narayanan K, Popov VL, Huang C, Inoue T, Peters CJ, Makino S.
Severe acute respiratory syndrome coronavirus 3a protein is a viral structural protein.
Journal of virology, 2005; 1.79(5): 3182-6.
www.wjpps.com Vol 9, Issue 6, 2020.
695
Suresh et al. World Journal of Pharmacy and Pharmaceutical Sciences
57. Schaecher SR, Mackenzie JM, Pekosz A. The ORF7b protein of severe acute respiratory
syndrome coronavirus (SARS-CoV) is expressed in virus-infected cells and incorporated
into SARS-CoV particles. Journal of virology, 2007; 15.81(2): 718-31.
58. Neuman BW, Joseph JS, Saikatendu KS, Serrano P, Chatterjee A, Johnson MA, Liao L,
Klaus JP, Yates JR, Wüthrich K, Stevens RC. Proteomics analysis unravels the functional
repertoire of coronavirus nonstructural protein 3. Journal of virology, 2008; 1.82(11):
5279-94.
59. Sawicki SG, Sawicki DL, Siddell SG. A contemporary view of coronavirus transcription.
Journal of virology, 2007; 1.81(1): 20-9.
60. National Health Commission of the People’s Republic of China. Diagnosis and Treatment
of Pneumonia Caused by 2019-nCoV (version 6).
2020. http://www.gov.cn/zhengce/zhengceku/2020-02/19/content_5480948.htm.
Accessed 18 Feb 2020.Return to ref 71 in article
61. WHO. Clinical management of severe acute respiratory infection when novel coronavirus
(nCoV) infection is suspected. https://www.who.int/publications-detail/clinical-
management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-
infection-is-suspected, 2020; 28: 1.
62. Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-
19. The Lancet Infectious Diseases, 2020; 1.20(4): 398-400.
63. Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, Tan KS, Wang DY, Yan Y. The
origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19)
outbreak–an update on the status. Military Medical Research, 2020; 7(1): 1-0.
64. Zumla A, Chan JF, Azhar EI, Hui DS, Yuen KY. Coronaviruses—drug discovery and
therapeutic options. Nature reviews Drug discovery, 2016; 15(5): 327.
65. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138
hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China.
JAMA. 2020. https://doi.org/10.1001/jama.2020; 1585.
66. Li H, Wang YM, Xu JY, Cao B. Potential antiviral therapeutics for 2019 Novel
Coronavirus. Zhonghua jie he he hu xi za zhi= Zhonghua jiehe he huxi zazhi= Chinese
journal of tuberculosis and respiratory diseases, 2020; 5.43: E002.
67. Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, Smith EC, Case JB,
Feng JY, Jordan R, Ray AS. Coronavirus susceptibility to the antiviral remdesivir (GS-
5734) is mediated by the viral polymerase and the proofreading exoribonuclease. MBio.
2018; 2.(2): e00221-18.
www.wjpps.com Vol 9, Issue 6, 2020.
696
Suresh et al. World Journal of Pharmacy and Pharmaceutical Sciences
68. https://doi.org/10.1128/mBio.00221-18.
69. Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. First case of
2019 novel coronavirus in the United States. N Engl J Med.
2020. https://doi.org/10.1056/NEJMoa2001191
70. Aguiar ACC, Murce E, Cortopassi WA, Pimentel AS, Almeida M, Barros DCS, et al.
Chloroquine analogs as antimalarial candidates with potent in vitro and in vivo activity.
Int J Parasitol Drugs Drug Resist, 2018; 8(3): 459–64.
71. Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral
infections: an old drug against today's diseases? Lancet Infect Dis, 2003; 3(11): 722–7.
72. Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, et al.
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J.,
2005; 2: 69.
73. Golden EB, Cho HY, Hofman FM, Louie SG, Schonthal AH, Chen TC. Quinoline-based
antimalarial drugs: a novel class of autophagy inhibitors. Neurosurg Focus, 2015; 38(3):
E12.
74. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G.
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus
(2019-nCoV) in vitro. Cell research, 2020; 30(3): 269-71.
75. Cvetkovic RS, Goa KL. Lopinavir/ritonavir: a review of its use in the management of
HIV infection. Drugs, 2003; 63(8): 769–802.
76. Arabi YM, Asiri AY, Assiri AM, Jokhdar HA, Alothman A, Balkhy HH, AlJohani S, Al
Harbi S, Kojan S, Al Jeraisy M, Deeb AM. Treatment of Middle East respiratory
syndrome with a combination of lopinavir/ritonavir and interferon-β1b (MIRACLE trial):
statistical analysis plan for a recursive two-stage group sequential randomized controlled
trial. Trials, 2020; 21(1): 1-8.
77. Chu CM, Cheng VC, Hung IF, Wong MM, Chan KH, Chan KS, et al. Role of
lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings.
Thorax, 2004; 59(3): 252–6.
78. Lim J, Jeon S, Shin HY, Kim MJ, Seong YM, Lee WJ, et al. Case of the index patient
who caused tertiary transmission of COVID-19 infection in Korea: the application of
lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by
quantitative RT-PCR. J Korean Med Sci, 2020; 35(6): e79.
79. Wang Z, Chen X, Lu Y, Chen F, Zhang W. Clinical characteristics and therapeutic
procedure for four cases with 2019 novel coronavirus pneumonia receiving combined
www.wjpps.com Vol 9, Issue 6, 2020.
697
Suresh et al. World Journal of Pharmacy and Pharmaceutical Sciences
Chinese and Western medicine treatment. Biosci Trends.
2020. https://doi.org/10.5582/bst.2020.01030
80. Neuraminidase inhibitors for treatment of influenza A and B infections. MMWR
Recomm Rep, 1999; 48: 1–9.
81. Bleibtreu A, Jaureguiberry S, Houhou N, Boutolleau D, Guillot H, Vallois D, Lucet JC,
Robert J, Mourvillier B, Delemazure J, Jaspard M. Clinical management of respiratory
syndrome in patients hospitalized for suspected Middle East respiratory syndrome
coronavirus infection in the Paris area from 2013 to 2016. BMC infectious diseases, 2018,
1.18(1): 331.
82. Al-Abdely HM, Midgley CM, Alkhamis AM, Abedi GR, Lu X, Binder AM, Alanazi KH,
Tamin A, Banjar WM, Lester S, Abdalla O. Middle East respiratory syndrome
coronavirus infection dynamics and antibody responses among clinically diverse patients,
Saudi Arabia. Emerging Infectious Diseases, 2019; 25(4): 753.
83. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, ssCheng Z.
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The
Lancet, 2020; 15.395(10223): 497-506.
84. Tai DY. Pharmacologic treatment of SARS: current knowledge and recommendations.
ANNALS-ACADEMY OF MEDICINE SINGAPORE, 2007; 1.36(6): 438.
85. Hoffmann M, Kleine-Weber H, Krüger N, Mueller MA, Drosten C, Pöhlmann S. The
novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the
cellular protease TMPRSS2 for entry into target cells. BioRxiv, 2020; 1.
86. Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, et al. Baricitinib as
potential treatment for 2019-nCoV acute respiratory disease. Lancet.
87. Sarma P, Prajapat M, Avti P, Kaur H, Kumar S, Medhi B. Therapeutic options for the
treatment of 2019-novel coronavirus: An evidence-based approach. Indian Journal of
Pharmacology, 2020; 52(1): 1.
88. https://www.worldometers.info/coronavirus/?utm_campaign=homeAdvegas1?
89. https://www.indiatoday.in/news-analysis/story/trade-in-the-time-of-covid-19-the-
economic-impact-of-coronavirus-on-india-and-beyond-1661118-2020-03-29
90. World Bank, ―World integrated trade solution,‖ accessed March 2, 2020.
https://www2.deloitte.com/us/en/insights/economy/covid-19/economic-impact-covid-
19.html